HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-02-07FDA Approved: MARAVIROC — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' original application for maraviroc, enabling a generic version of the HIV entry inhibitor.
-
FDA approval · 2022-02-02FDA Approved: ATAZANAVIR — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approves Camber Pharmaceuticals' generic atazanavir (atazanavir) under an original drug application. The generic is indicated for th…
-
FDA approval · 2022-01-31FDA Approved: EDURANT — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for Edurant (rilpivirine hydrochloride) submitted by Janssen Products, LP.
-
FDA approval · 2022-01-31FDA Approved: CABENUVA — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for CABENUVA (cabotegravir and rilpivirine) to update its labeling for use as a complete regimen in …
-
FDA approval · 2022-01-27FDA Approved: PIFELTRO — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for PIFELTRO (doravirine) by Merck Sharp & Dohme LLC, expanding its label for HIV-1 infection.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-01-27FDA Approved: DELSTRIGO — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Delstrigo, a fixed-dose combination HIV-1 therapy (doravirine/lamivudine/tenofovir disoproxi…
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. [Phase 2]
A Phase 2 open-label randomized trial evaluating valganciclovir for reducing mortality in severe IRIS-Kaposi sarcoma; completed with results…
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: Second-line Switch to Dolutegravir Study [Phase 4]
A Phase 4 clinical trial examining switching to dolutegravir as a second-line therapy for HIV-1 infection has been completed.
-
FDA approval · 2022-01-24FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved a generic fixed-dose combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate for treatment of…
-
FDA approval · 2022-01-24FDA Approved: RUKOBIA — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Rukobia (fostemsavir tromamine) from ViiV Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2022-01-24Clinical Trial Update: Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy [Phase 2, Phase 3]
Clinical trial evaluating switching to VM-1500A-LAI + 2 NRTIs from first-line ART for HIV-1 infection (Phase 2/3).
-
EMA withdrawal · 2022-01-21EMA Withdrawn: Atripla (efavirenz;emtricitabine;tenofovir disoproxil fumarate) — Gilead Sciences Ireland UC
EMA has withdrawn Atripla (efavirenz; emtricitabine; tenofovir disoproxil fumarate) from the market; therapeutic area: HIV infections.
-
FDA approval · 2022-01-20FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental NDA for Dovato (dolutegravir and lamivudine) from ViiV Healthcare Company. This action approves a modification/e…
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users [Phase 2]
Phase 2 trial evaluating a smartphone intervention to improve HAART adherence among people with HIV and drug use disorders has completed.
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
A prospective longitudinal study investigating endothelial function in HIV/HCV coinfected individuals; trial completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: Prospective Cohort Study of HIV and Zika in Infants and Pregnancy
A completed prospective cohort study evaluating HIV and Zika outcomes in infants and pregnancy with posted results.
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA® [Phase 1, Phase 2]
Open-label, randomized study assessing efficacy, safety and dose selection of VM-1500A-LAI in HIV-1-infected patients transitioning from NNR…
-
FDA approval · 2022-01-07FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) to update its l…
-
CLINICAL_TRIALS trial_result · 2022-01-03Clinical Trial Update: Early ART to Limit Infection and Establishment of Reservoir [Phase 2]
Phase 2 trial update reporting results from starting antiretroviral therapy early to limit HIV infection and prevent establishment of viral …
-
CLINICAL_TRIALS trial_result · 2021-12-29Clinical Trial Update: MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South [NA]
A completed clinical trial (MySTYLE) evaluating online family-based HIV prevention for non-heterosexual Black adolescent males in the South;…
-
CLINICAL_TRIALS trial_result · 2021-12-23Clinical Trial Update: Efficacy and Safety of Low-Dose Colchicine on Surrogate Markers of Cardiovascular Events in People Living With HIV Receiving Antiretroviral Therapy [Phase 4]
Phase 4 trial evaluating low-dose colchicine for efficacy and safety on surrogate cardiovascular markers in people living with HIV on antire…
-
FDA approval · 2021-12-22FDA Approved: RITONAVIR FILM COATED — Supplemental Application (Cipla USA Inc.)
FDA approved Cipla USA's supplemental application to add a film-coated 100 mg ritonavir tablet to the approved product, expanding the dosage…
-
FDA approval · 2021-12-22FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Original Application (Laurus Labs Limited)
FDA approved Laurus Labs' generic fixed-dose combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate for t…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants [Phase 3]
Phase 3 trial update noting continued access to etravirine for treatment-experienced HIV-1 infected participants, with results posted in Dec…
-
FDA approval · 2021-12-20FDA Approved: VOCABRIA — Supplemental Application (ViiV Healthcare Company)
The FDA has approved a supplemental application for VOCABRIA (cabotegravir sodium) from ViiV Healthcare Company. This action supplements the…